Campbell & CO Investment Adviser LLC Kiniksa Pharmaceuticals, Ltd. Transaction History

Campbell & CO Investment Adviser LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$17.63 - $21.74 $11,018 - $13,587	-625 Reduced 2.7%	22,557 $445,000
Q4 2023 Feb 13, 2024	SELL	$14.37 - $19.07 $125,205 - $166,156	-8,713 Reduced 27.32%	23,182 $406,000
Q3 2023 Nov 08, 2023	SELL	$13.62 - $20.2 $345,661 - $512,655	-25,379 Reduced 44.31%	31,895 $554,000
Q2 2023 Aug 11, 2023	BUY	$10.44 - $16.48 $292,654 - $461,967	28,032 Added 95.86%	57,274 $806,000
Q1 2023 May 11, 2023	SELL	$10.7 - $15.79 $388,281 - $572,987	-36,288 Reduced 55.38%	29,242 $314,000
Q4 2022 Feb 14, 2023	BUY	$11.42 - $17.05 $133,454 - $199,246	11,686 Added 21.7%	65,530 $981,000
Q3 2022 Nov 14, 2022	BUY	$9.76 - $13.41 $525,517 - $722,048	53,844 New	53,844 $691,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $687M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.